Actelion nominates Mr. John J. Greisch for election to the Board of Directors

Thu Mar 14, 2013 2:01am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130314:nHUGcZ9J



Actelion Pharmaceuticals Ltd / Actelion nominates Mr. John J. Greisch for election to the Board of
Directors . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for
the content of this announcement. 


ALLSCHWIL/BASEL, SWITZERLAND - 14 March 2013- Actelion Ltd (SIX: ATLN) today issued the formal
invitation to the upcoming Annual General Meeting (AGM) of shareholders on behalf of the Board of
Directors.

At the AGM the Board is nominating Mr. John J. Greisch to the Board of Directors. Mr. Greisch is
currently serving as the President and Chief Executive Officer of Hill-Rom Holdings, Inc.

Jean-Pierre Garnier, Chairman of the Board of Directors, commented: "As a current CEO, John
understands the challenges that face companies operating in the current economic and business
climate. I believe John's strong track record of success in the healthcare industry will add
significant practical business acumen to Actelion's Board."

In addition, delivering on Actelion's commitment to value creation for all stakeholders, the Board
is proposing a 25% increase in the dividend payment, increasing the payment to CHF 1.00 per share
 

AGENDA FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2013

1Approval of the Business Report consisting of the Annual Report, the Annual Statutory Accounts
and the Consolidated Accounts as of 31 December 2012 
2Appropriation of Available Earnings and Distribution Against Reserve from Capital Contribution
3Consultative Vote on Compensation Report
4Discharge of the Board of Directors and of the Senior Management
5Reduction of Share Capital by Cancellation of Repurchased Shares
6Board Elections6.1  Re-Election of Mr. Werner Henrich6.2 Re-Election of Mr. Armin Kessler6.3  
Re-Election of Mr. Jean Malo6.4   Election of Mr. John J. Greisch as New Board Member
7Election of the Statutory Auditors

NOTES TO SHAREHOLDERS

The Annual General Meeting of Shareholders to approve the Business Report of the year ending 31
December 2012 will be held on 18 April 2013 at 14.00 CEST at the Congress Center, Messe Basel,
Switzerland.

The invitation has been published in the Swiss Official Gazette of Commerce (Schweizerisches
Handelsamtsblatt) and is available, together with the company's Annual Report, on
www.actelion.com.

In order to attend and vote at the Annual General Meeting of Shareholders, shareholders must have
been registered in the Company's shareholder register by 9 April 2013 at the latest.

 

###

 

NOTES TO EDITORS

ABOUT MR JOHN J. GREISCH

Mr. John J. Greisch is currently President (as Executive Director) and Chief Executive Officer of
Hill-Rom Holdings, Inc., a leading medical supplier of patient support systems such as hospital
beds, therapeutic surfaces and stretchers. Under Mr. Greisch's leadership, Hill-Rom increased its
investments in research and development, introducing new smart bed technology and new surfaces to
the market as well as expanding its Singapore-based Asia-Pacific Innovation Center.

Before joining Hill-Rom, Mr. Greisch spent seven years at Baxter International, Inc. in various
executive positions in corporate finance, operations and general management. From 2004-2006, he
served as Chief Financial Officer and from 2006-2009 as President International Operations.

Mr Greisch earned a Bachelor's degree in Business Administration from the Miami University, US and
a Master's Degree in Management (MBA equivalent) from the Northwestern University in Illinois, US

Mr. Greisch also serves on the Board of Lurie Children's Hospital in Chicago and is a past member
of the Business School Advisory Board for Miami University's Farmer School of Business.

 

ABOUT ACTELION LTD.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel,
Switzerland.  Actelion's first drug Tracleer(R), an orally available dual endothelin receptor
antagonist, has been approved as a therapy for pulmonary arterial hypertension.  Actelion markets
Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States
(based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland.

Founded in late 1997 Actelion is a leading player in innovative science related to the endothelium
- the single layer of cells separating every blood vessel from the blood stream.  Actelion's over
2,400 employees focus on the discovery, development and marketing of innovative drugs for
significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R)).

For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com http://www.actelion.com/

Media Release PDF http://hugin.info/131801/R/1685097/551972.pdf 


----------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE


HUG#1685097



 --- End of Message --- 

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.